267 related articles for article (PubMed ID: 8687021)
1. Oxidative stress and Parkinson's disease.
Owen AD; Schapira AH; Jenner P; Marsden CD
Ann N Y Acad Sci; 1996 Jun; 786():217-23. PubMed ID: 8687021
[TBL] [Abstract][Full Text] [Related]
2. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
[TBL] [Abstract][Full Text] [Related]
3. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
Jenner P
Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.
Jenner P; Dexter DT; Sian J; Schapira AH; Marsden CD
Ann Neurol; 1992; 32 Suppl():S82-7. PubMed ID: 1510385
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease.
Han J; Cheng FC; Yang Z; Dryhurst G
J Neurochem; 1999 Oct; 73(4):1683-95. PubMed ID: 10501216
[TBL] [Abstract][Full Text] [Related]
6. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration.
Toffa S; Kunikowska GM; Zeng BY; Jenner P; Marsden CD
J Neural Transm (Vienna); 1997; 104(1):67-75. PubMed ID: 9085194
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease.
Merad-Boudia M; Nicole A; Santiard-Baron D; Saillé C; Ceballos-Picot I
Biochem Pharmacol; 1998 Sep; 56(5):645-55. PubMed ID: 9783733
[TBL] [Abstract][Full Text] [Related]
9. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
[TBL] [Abstract][Full Text] [Related]
10. [Effect of electroacupuncture intervention on levels of SOD, GSH, GSH-Px, MDA, and apoptosis of dopaminergic neurons in substantia Nigra in rats with Parkinson's disease].
Li J; Wang LN; Xiao HL; Li X; Yang JJ
Zhen Ci Yan Jiu; 2014 Jun; 39(3):185-91. PubMed ID: 25069193
[TBL] [Abstract][Full Text] [Related]
11. What process causes nigral cell death in Parkinson's disease?
Jenner P
Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
13. Glutathione, iron and Parkinson's disease.
Bharath S; Hsu M; Kaur D; Rajagopalan S; Andersen JK
Biochem Pharmacol; 2002 Sep; 64(5-6):1037-48. PubMed ID: 12213603
[TBL] [Abstract][Full Text] [Related]
14. Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain.
Seaton TA; Jenner P; Marsden CD
J Neural Transm (Vienna); 1996; 103(3):315-29. PubMed ID: 8739843
[TBL] [Abstract][Full Text] [Related]
15. [Effect and mechanism of moxibustion on oxidative stress injury in rats with Parkinson's disease by activating Nrf2/ARE pathway].
Liu XL; Lu J; Tian Y; Zhang GY; Zhao CP; Wang TT; Li XR; Zhu ML
Zhongguo Zhen Jiu; 2020 Aug; 40(8):857-62. PubMed ID: 32869595
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson's Disease.
Voshavar C; Shah M; Xu L; Dutta AK
Neurotox Res; 2015 Nov; 28(4):302-18. PubMed ID: 26201265
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease: a disorder due to nigral glutathione deficiency?
Perry TL; Godin DV; Hansen S
Neurosci Lett; 1982 Dec; 33(3):305-10. PubMed ID: 7162692
[TBL] [Abstract][Full Text] [Related]
18. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
Youdim MB; Riederer P
J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
[TBL] [Abstract][Full Text] [Related]
19. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease.
Sofic E; Lange KW; Jellinger K; Riederer P
Neurosci Lett; 1992 Aug; 142(2):128-30. PubMed ID: 1454205
[TBL] [Abstract][Full Text] [Related]
20. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
